Jared P Beller1, Elizabeth D Krebs1, Robert B Hawkins1, J Hunter Mehaffey1, Mohammed A Quader2, Alan M Speir3, Andy C Kiser4, Mark Joseph5, Leora T Yarboro1, Nicholas R Teman1, Gorav Ailawadi6. 1. Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, Va. 2. Division of Cardiothoracic Surgery, Virginia Commonwealth University, Richmond, Va. 3. INOVA Heart and Vascular Institute, Falls Church, Va. 4. Cardiovascular Services, St Clair Hospital, Pittsburgh, Pa. 5. Division of Cardiothoracic Surgery, Virginia Tech Carillion School of Medicine, Roanoke, Va. 6. Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, Va. Electronic address: Gorav@virginia.edu.
Abstract
OBJECTIVE: The prevalence of non-vitamin K oral anticoagulant use after cardiac surgery is unknown, particularly in patients with bioprosthetic valves. We sought to define the contemporary use and short-term safety of non-vitamin K oral anticoagulants after cardiac surgery. METHODS: All patients undergoing bioprosthetic aortic valve replacement, bioprosthetic mitral valve replacement, or isolated coronary artery bypass grafting (2011-2018) were evaluated from a multicenter, regional Society of Thoracic Surgeons database. Patients were stratified by anticoagulant type (non-vitamin K oral anticoagulant vs vitamin K antagonist) and era (early [2011-2014] vs contemporary [2015-2018]). RESULTS: Of 34,188 patients, 18% (6063) were discharged on anticoagulation, of whom 23% were prescribed non-vitamin K oral anticoagulants. Among those receiving anticoagulation, non-vitamin K oral anticoagulant use has significantly increased from 10.3% to 35.4% in contemporary practice (P < .01). This trend was observed for each operation type (coronary artery bypass grafting 0.86%/year, bioprosthetic aortic valve replacement: 2.15%/year, bioprosthetic mitral valve replacement: 2.72%/year, all P < .01). In patients with postoperative atrial fibrillation receiving anticoagulation, non-vitamin K oral anticoagulant use has increased from 6.3% to 35.4% and 12.3% to 40.3% after bioprosthetic valve replacement and isolated coronary artery bypass grafting, respectively (both P < .01). In patients receiving anticoagulation at discharge, adjusted 30-day mortality (odds ratio, 1.94; P = .12) and reoperation (odds ratio, 0.79; P = .34) rates were not associated with anticoagulant choice, whereas non-vitamin K oral anticoagulant use was associated with an adjusted 0.9-day decrease (P < .01) in postoperative length of stay. CONCLUSIONS: Non-vitamin K oral anticoagulant use after cardiac surgery has dramatically increased since 2011. This trend is consistent regardless of indication for anticoagulation including bioprosthetic valves. Short-term outcomes support their safety in the cardiac surgery setting with shorter postoperative hospital stays. Long-term studies on the efficacy of non-vitamin K oral anticoagulants after cardiac surgery are still necessary.
OBJECTIVE: The prevalence of non-vitamin K oral anticoagulant use after cardiac surgery is unknown, particularly in patients with bioprosthetic valves. We sought to define the contemporary use and short-term safety of non-vitamin K oral anticoagulants after cardiac surgery. METHODS: All patients undergoing bioprosthetic aortic valve replacement, bioprosthetic mitral valve replacement, or isolated coronary artery bypass grafting (2011-2018) were evaluated from a multicenter, regional Society of Thoracic Surgeons database. Patients were stratified by anticoagulant type (non-vitamin K oral anticoagulant vs vitamin K antagonist) and era (early [2011-2014] vs contemporary [2015-2018]). RESULTS: Of 34,188 patients, 18% (6063) were discharged on anticoagulation, of whom 23% were prescribed non-vitamin K oral anticoagulants. Among those receiving anticoagulation, non-vitamin K oral anticoagulant use has significantly increased from 10.3% to 35.4% in contemporary practice (P < .01). This trend was observed for each operation type (coronary artery bypass grafting 0.86%/year, bioprosthetic aortic valve replacement: 2.15%/year, bioprosthetic mitral valve replacement: 2.72%/year, all P < .01). In patients with postoperative atrial fibrillation receiving anticoagulation, non-vitamin K oral anticoagulant use has increased from 6.3% to 35.4% and 12.3% to 40.3% after bioprosthetic valve replacement and isolated coronary artery bypass grafting, respectively (both P < .01). In patients receiving anticoagulation at discharge, adjusted 30-day mortality (odds ratio, 1.94; P = .12) and reoperation (odds ratio, 0.79; P = .34) rates were not associated with anticoagulant choice, whereas non-vitamin K oral anticoagulant use was associated with an adjusted 0.9-day decrease (P < .01) in postoperative length of stay. CONCLUSIONS: Non-vitamin K oral anticoagulant use after cardiac surgery has dramatically increased since 2011. This trend is consistent regardless of indication for anticoagulation including bioprosthetic valves. Short-term outcomes support their safety in the cardiac surgery setting with shorter postoperative hospital stays. Long-term studies on the efficacy of non-vitamin K oral anticoagulants after cardiac surgery are still necessary.
Authors: Anthony P Carnicelli; Raffaele De Caterina; Jonathan L Halperin; Giulia Renda; Christian T Ruff; Marco Trevisan; Francesco Nordio; Michele F Mercuri; Elliott Antman; Robert P Giugliano Journal: Circulation Date: 2017-02-16 Impact factor: 29.690
Authors: Alvaro Avezum; Renato D Lopes; Phillip J Schulte; Fernando Lanas; Bernard J Gersh; Michael Hanna; Prem Pais; Cetin Erol; Rafael Diaz; M Cecilia Bahit; Jozef Bartunek; Raffaele De Caterina; Shinya Goto; Witold Ruzyllo; Jun Zhu; Christopher B Granger; John H Alexander Journal: Circulation Date: 2015-06-23 Impact factor: 29.690
Authors: Gorav Ailawadi; Damien J LaPar; Alan M Speir; Ravi K Ghanta; Leora T Yarboro; Ivan K Crosby; D Scott Lim; Mohammed A Quader; Jeffrey B Rich Journal: Ann Thorac Surg Date: 2015-09-26 Impact factor: 4.330
Authors: Thomas A Schwann; Robert H Habib; Rakesh M Suri; J Matthew Brennan; Xia He; Vinod H Thourani; Milo Engoren; Gorav Ailawadi; Brian R Englum; Mark R Bonnell; James S Gammie Journal: Chest Date: 2016-04-29 Impact factor: 9.410
Authors: Günter Breithardt; Helmut Baumgartner; Scott D Berkowitz; Anne S Hellkamp; Jonathan P Piccini; Susanna R Stevens; Yuliya Lokhnygina; Manesh R Patel; Jonathan L Halperin; Daniel E Singer; Graeme J Hankey; Werner Hacke; Richard C Becker; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf Journal: Eur Heart J Date: 2014-08-22 Impact factor: 29.983
Authors: André Rodrigues Durães; Pollianna de Souza Roriz; Bianca de Almeida Nunes; Felipe Pinho E Albuquerque; Fábio Vieira de Bulhões; Andre Mauricio de Souza Fernandes; Roque Aras Journal: Drugs R D Date: 2016-06
Authors: José A López-López; Jonathan A C Sterne; Howard H Z Thom; Julian P T Higgins; Aroon D Hingorani; George N Okoli; Philippa A Davies; Pritesh N Bodalia; Peter A Bryden; Nicky J Welton; William Hollingworth; Deborah M Caldwell; Jelena Savović; Sofia Dias; Chris Salisbury; Diane Eaton; Annya Stephens-Boal; Reecha Sofat Journal: BMJ Date: 2017-11-28